Skip to content

Retrospective analysis of cerebral glucose metabolism patterns in DOC patients after ischemic-hypoxic brain injury

Retrospective analysis of cerebral glucose metabolism patterns in DOC patients after ischemic-hypoxic brain injury

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200060243
Enrollment
Unknown
Registered
2022-05-23
Start date
2022-05-18
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

DOC patients after ischemic-hypoxic brain injury

Interventions

Consciousness disorders group:None
Control group:None

Sponsors

Huashan Hospital,Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria for patients with hypoxic ischemic encephalopathy (HIE): 1. Age >= 18 years old and= 2 months; 4. There is a disturbance of consciousness that has been assessed as vegetative or minimally conscious by the Coma Recovery Scale - Revised Edition; 5. FDG-PET brain imaging has been completed; 6. Right handedness before onset; The legal representative of the subject can understand and sign the informed consent form. Inclusion criteria for healthy subjects: 1. Age >= 18 years old and<80 years old, regardless of gender; 2. Previously in good health, I came to the PET Center of Huashan Hospital to undergo a full body FDG-PET scan for the purpose of physical examination; 3. Brain FDG-PET scanning has been completed; 4. Right handed; 5. The subject himself or her legal representative can understand and sign the informed consent form.

Exclusion criteria

Exclusion criteria: Exclusion criteria for patients with hypoxic ischemic encephalopathy (HIE): 1. Have previously experienced diseases that cause brain parenchymal damage such as cerebrovascular diseases, brain trauma, intracranial tumors, and central nervous system neuritis; 2. Progressive deterioration of consciousness or new neurological deficits within 2 weeks before PET brain imaging; 3. Those who are participating in other clinical trials when performing PET brain imaging, or have participated in clinical trials of drugs or invasive treatment, or have participated in clinical trials of non-invasive treatment within 6 months before PET brain imaging; 4. When PET brain imaging is performed, there are serious systemic diseases, including but not limited to: acute coronary artery disease, heart failure, unstable angina or arrhythmia, uremia, liver failure, sudden stroke, acute myocardial infarction, unstable diabetes, uncontrolled chronic obstructive pulmonary disease, uncontrolled hypertension, uncontrolled epilepsy, sepsis or serious infectious diseases, Or a previous history of mental disorders and severe depression, or significant abnormalities in laboratory tests, clinically significant or unstable conditions, or a history of drug abuse or alcoholism; 5. Previous clinical conditions that the moderator of this study believes may have an impact or potential impact on the results of this study. Exclusion criteria for healthy subjects: 1. Have previously experienced diseases that cause brain parenchymal damage such as cerebrovascular diseases, brain trauma, intracranial tumors, and central nervous system neuritis; 2. Past serious systemic diseases, including but not limited to: acute coronary artery disease, heart failure, unstable angina or arrhythmia, uremia, liver failure, sudden stroke, acute myocardial infarction, unstable diabetes, uncontrolled chronic obstructive pulmonary disease, uncontrolled hypertension, uncontrolled epilepsy, sepsis or serious infectious diseases, Or has a previous history of mental disorders and severe depression, or has significant abnormalities in laboratory tests, clinically significant or unstable conditions, or a history of drug abuse or alcoholism; 3. The whole body FDG-PET scan reveals abnormalities in the nervous system or other organs that the moderator of this study believes may have an impact or potential impact on the results of this study; 4. During pregnancy or lactation; 5. The subject has other clinical conditions that the moderator of the study believes may have an impact or potential impact on the results of the study.

Design outcomes

Primary

MeasureTime frame
Connors Behavior Rating Scale;PET-CT;

Secondary

MeasureTime frame
GCS score;

Countries

China

Contacts

Public ContactHe Zhijie

Huashan Hospital, Fudan University

Hezhijie@fudan.edu.cn+86 21 52887820

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026